David Joseph Topper - 22 Nov 2022 Form 4 Insider Report for Frazier Lifesciences Acquisition Corp

Role
Chief Financial Officer, Director
Signature
/s/ David Topper
Issuer symbol
N/A
Transactions as of
22 Nov 2022
Net transactions value
$0
Form type
4
Filing time
23 Nov 2022, 15:31:11 UTC
Next filing
11 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FLAC Class B Ordinary Shares Options Exercise -30,000 -100% 0 22 Nov 2022 Class A Ordinary Shares 30,000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

David Joseph Topper is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022.